The opportunity is enormous, but uncertainty remains.

The EU has eased restrictions on crops developed using novel genetic techniques. While supporters say the technology could ...

They have at least one thing in common: An exciting pipeline.

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with ...

Researchers from Skoltech—a VEB.RF group institution—and their colleagues from the U.S. and China have explained how the ...

Scribe awarded more than $25M from CIRM to accelerate additional CRISPR-based gene editing therapies for cardiometabolic ...

View CRISPR Therapeutics AG CRSP stock quote prices, financial information, real-time forecasts, and company news from CNN.

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first Phase III study of an in vivo CRISPR therapy. In this large-scale, double-blind trial, 80 ...

Phase III trial shows majority of patients become attack-free without ongoing meds ...